Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cadonilimab + THIO |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cadonilimab | AK-104|AK 104|AK104 | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 136 | Cadonilimab is a bispecific antibody that targets CD274 (PD-L1) and CTLA-4, potentially resulting in enhanced anti-tumor immune response (PMID: 36872527). | |
| THIO | 6-thio-2'-deoxyguanosine|6-thio-dG|ateganosine | THIO (6-thio-2'-deoxyguanosine) is precursor nucleoside analogue that incorporates into newly synthesized telomeres, leading to telomere dysfunction and apoptosis in telomerase-positive cells, and potential anti-tumor activity (PMID: 34593527; PMID: 25516420). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07446257 | Phase I | THIO Cadonilimab Cadonilimab + THIO | THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | Not yet recruiting | USA | 0 |